{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-001799","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.159053+00:00","generated_at":"2026-05-26T01:07:33.338230+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Collegium reports record Q4 revenue $181.9M, GAAP EPS $0.36; EVP Shirley Kuhlmann departing March 7","bullets":["Q4 product revenue $181.9M (+22% YoY); GAAP net income $12.5M ($0.36 diluted EPS); adjusted EBITDA $107.7M.","FY2024 product revenue $631.4M (+11% YoY); GAAP net income $69.2M ($1.86 diluted EPS); adjusted EBITDA $401.2M.","Jornay PM pro forma FY2024 net rev $100.7M; expects >$135M in 2025. Belbuca Q4 net rev $55.2M (+12% YoY); Xtampza ER $51.5M (+6% YoY).","Reaffirmed FY2025 guidance: product revenue $735-750M, adj EBITDA $435-450M. Repurchased $60M in shares in 2024; cash $162.8M.","EVP, Chief Admin Officer, General Counsel & Secretary Shirley Kuhlmann stepping down effective March 7, 2025; treated as termination without cause."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-001799","json":"https://secwatch.observer/filing/0001558370-25-001799.json","markdown":"https://secwatch.observer/filing/0001558370-25-001799.md","text":"https://secwatch.observer/filing/0001558370-25-001799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000155837025001799/0001558370-25-001799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000155837025001799/coll-20250227x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:07:33.338230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fcab5da270","claim":"Shirley Kuhlmann departed as Executive Vice President, Chief Administrative Officer, General Counsel & Secretary at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"On February 27, 2025, the Company announced that Shirley Kuhlmann, Executive Vice President, Chief Administrative Officer, General Counsel & Secretary of the Company will step down from her positions at the Company effective March 7, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837025001799/0001558370-25-001799-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepping down"},{"label":"Role","value":"Executive Vice President, Chief Administrative Officer, General Counsel & Secretary"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}